bluebird bio Announces Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple Myeloma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to bluebird bio Announces Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple Myeloma
BLUEBIRD BIO (NASDAQ: BLUE) Delayed: 4.97 --0 (-0%)
Previous Close $4.97    52 Week High $95.28 
Open $4.97    52 Week Low $35.37 
Day High $4.97    P/E N/A 
Day Low $4.97    EPS $-1.81 
Volume 5